Tracy Song appointed as Chief Financial Officer (CFO) of ImmuneOnco
Shanghai, China, July 26, 2021
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that Ms.Tracy(Ziyi) Song has been appointed as the Chief Financial Officer (CFO) of the company, reporting to Dr. Wenzhi Tian, Chairman and founder of ImmuneOnco. Ms. Song will be responsible for the IPO financial transactions and financial strategy of ImmuneOnco
Ms. Song holds a bachelor's degree in Economics and Mathematics from the University of Chicago in the United States. She has over 15 years of experience in international investment banking and investment management in the medical field. She has rich capital market experience in IPO, financing, M&A and other capital markets, and was responsible for the completion of more than 50 capital market transactions during her investment banking. Prior to joining ImmuneOnco, Ms. Song held key positions at Bank of America Merrill Lynch, UBS and CITIC Lyon. She was responsible for investment strategy planning and investment management in the fund of healthcare industry in the Greater Bay Area Fund. She will receive a Master's degree in Medicine from the School of Medicine of Hong Kong University.
Ms. Song said, "It is a great honor to join ImmuneOnco, which has leading technology and R&D capabilities, a first-class team and a globally competitive oncology innovative drug pipeline platform. I am fully confident in ImmuneOnco’s future. I look forward to working with ImmuneOnco to promote the rapid development of investment and financing business together and make my best contribution to the international development of ImmuneOnco."
Dr. Tian Wenzhi, the Chairman and founder, said, "I am very pleased to welcome Tracy to join the team of ImmuneOnco. I believe that she will definitely help the company to enter the capital market smoothly with her rich professional experience. We also look forward to her joining us to accelerate the realization of ImmuneOnco with great vision of 'developing first-class new drugs for the benefit of cancer patients'." "We will work with all our colleagues to build the company into a world-renowned biopharmaceutical company, and develop first-in-class anti-cancer drugs for cancer patients around the world".
Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bispecific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can gradually return to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.
For further cooperation, please contact
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573